4-[2-(Morpholine-4-sulfonyl)-ethyl]-phenylamine → 8-Indan-5-yl-2-{4-[2-(morpholine-4-sulfonyl)-ethyl]-phenylamino}-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester

Participants

Reaction Steps

Using the procedure outlined in Example 1(g) the title compound was prepared from 4-[2-(morpholine-4-sulfonyl)-ethyl]-phenylamine (65 mg, 0.24 mmol) and 8-indan-5-yl-2-ethanesulfonyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester (from Example 1(e) above, 100 mg, 0.24 mmol). The title compound was obtained as a white solid (42 mg, 29%). 1H NMR (400 MHz, CDCl3) δ (ppm): 9.35 (s, 1H), 8.53 (s, 1H), 8.01 (br, 1H), 7.42 (d, J=7.8 Hz, 1H), 7.30 (m, 3H), 7.19 (d, J=7.8 Hz, 1H), 6.94 (br, 2H), 4.37 (q, J=7.1 Hz, 2H), 3.72 (t, J=4.5 Hz, 4H), 3.25 (t, J=4.7 Hz, 4H), 3.08 (m, 6H), 3.01 (t, J=7.4 Hz, 2H), 2.24 (m, 2H), 1.38 (t, J=7.1 Hz, 3H).

Provenance & Evidence